Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.